Literature DB >> 23563237

STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia.

R S Ohgami1, L Ma, J D Merker, B Martinez, J L Zehnder, D A Arber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23563237     DOI： 10.1038/leu.2013.104

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  35 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 2.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

3.  STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Authors:  Robert S Ohgami; Lisa Ma; Ahmad Monabati; James L Zehnder; Daniel A Arber
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

4.  The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.

Authors:  Hanna L M Rajala; Thomas Olson; Michael J Clemente; Sonja Lagström; Pekka Ellonen; Tuija Lundan; David E Hamm; Syed Arshi Uz Zaman; Jesus M Lopez Marti; Emma I Andersson; Andres Jerez; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Satu Mustjoki
Journal:  Haematologica       Date:  2014-10-03       Impact factor: 9.941

5.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Authors:  Can Küçük; Bei Jiang; Xiaozhou Hu; Wenyan Zhang; John K C Chan; Wenming Xiao; Nathan Lack; Can Alkan; John C Williams; Kendra N Avery; Pınar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Weiping Liu; Kai Fu; Laurence de Leval; Timothy McKeithan; Wing C Chan
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

Review 6.  Vitamin D in hematological disorders and malignancies.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; David J Feith; Thomas P Loughran
Journal:  Eur J Haematol       Date:  2016-11-21       Impact factor: 2.997

Review 7.  The Ying and Yang of STAT3 in Human Disease.

Authors:  Tiphanie P Vogel; Joshua D Milner; Megan A Cooper
Journal:  J Clin Immunol       Date:  2015-08-18       Impact factor: 8.317

Review 8.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

9.  Distinct mutations at the same positions of STAT3 cause either loss or gain of function.

Authors:  Prabha Chandrasekaran; Ofer Zimmerman; Michelle Paulson; Elizabeth P Sampaio; Alexandra F Freeman; Kathryn J Sowerwine; Darell Hurt; Julio C Alcántara-Montiel; Amy P Hsu; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2016-05-24       Impact factor: 10.793

Review 10.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.

Authors:  Geoffrey Shouse; Liana Nikolaenko
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.